CONSULTANT PUBLICATIONS

Sandy McEwan

MD, MB, FRCPC, FSNMMI

 

PUBLICATIONS

  1. Hans-S Jans, Daria Stypinski, Piyush Kumar , John R Mercer, Stephen A McQuarrie, Alexander J B McEwan, Leonard I Wiebe, Radiation Dosimetry of Theragnostic Pairs for Isotopes of Iodine in IAZA, Pharmaceutics, 2022 Aug 9;14(8):1655. doi: 10.3390/pharmaceutics14081655.
  2. Terence A Riauka, Vickie E Baracos, Rebecca Reif, Freimut D Juengling, Don M Robinson, Marguerite Wieler, Alexander J B McEwan, Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PET-A Significant Improvement Over Prediction Equations, Front Oncol. 2022 Jul 7;12:812777, doi: 10.3389/fonc.2022.812777
  3. Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey- Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2022 Mar;63(3):376-383. doi: 10.2967/jnumed.121.261936.
  4. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. Miller CG, Grønbæk H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, McEwan S. EJNMMI Res. 2021 Sep 6;11(1):84. doi: 10.1186/s13550-021-00819-1.
  5. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. Miller CG, Grønbæk H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, McEwan S. EJNMMI Res. 2021 Sep 6;11(1):84. doi: 10.1186/s13550-021-00819-1.
  6. Saravana-Bawan B, Bajwa A, Paterson J, McEwan AJB, McMullen TPW, Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta- analysis. Clin Nucl Med. 2019 Sep;44(9):719-727. doi: 10.1097/0000000000002646.
  7. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018 Nov 1;4(11):1597-1604. doi: 10.1001/jamaoncol.2018.242
  8. Chu KP, Baker S, Zenke J, Morad A, Ghosh S, Morrish DW, McEwan AJBS, Williams DC, Severin D, McMullen TPW. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence. Thyroid. 2018 Jul;28(7):902-912. doi: 10.1089/thy.2017.0136.
  9. Stypinski D, McQuarrie SA, McEwan AJB, Wiebe LI. Pharmacokinetics and Scintigraphic Imaging of the Hypoxia-Imaging Agent [123I]IAZA in Healthy Adults Following Exercise-Based Cardiac Stress. Pharmaceutics. 2018 Feb 22;10(1):25. doi: 10.3390/pharmaceutics10010025
  10. Cai XY, Vijayaratnam N, McEwan AJB, Reif R, Morrish DW. Comparison of 30 mCi and 50 mCi I-131 doses for ablation of thyroid remnant in papillary thyroid cancer patients. Endocr Res. 2018 Feb;43(1):11-14. doi: 10.1080/07435800.2017.1346662. Epub 2017 Jul 25.
  11. McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D, A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours., Citation: CAN J SURG. Apr 2017;60 (3):7616.
  12. Rahimi B, Makis W, Riauka TA, McEwan AJ, Morrish D, 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis., Citation: CLIN NUCL MED. May 2017;42 (5):350-353.
  13. Selivanova S, Lavallée É, Senta H, Caouette L, McEwan AJ, Guérin B, Lecomte R, Turcotte E, Clinical Trial Using Sodium Pertechnetate 99mTc Produced with Medium-Energy Cyclotron: Biodistribution and Safety Assessment in Patients with Abnormal Thyroid Function., J Nucl Med. 2016 Oct 13. pii: jnumed.116.178509.
  14. Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJ, Castellani R, Lynch T, Shulkin B, Drobics M, Staudenherz A, Ladenstein R, 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel., Citation: EUR J NUCL MED MOL I. Feb 2017;44 (2):234-241.rediction of hip fracture in elderly women. Miller CG, Porter RW. British Medical Journal 1991; 302:50 (letter to the editor).
  15. Andersson JD, Wilson JS, Romaniuk JA, McEwan AJ, Abrams DN, McQuarrie SA, Gagnon K, Separation of [(99m) Tc] pertechnetate and molybdate using polyethylene glycol coated C18 and C30 resins. Appl. Radiat. Isot. 2016; 110:193-9. DOI:10.1016/j.apradiso.2016.01.016
  16. Makis W1, Robinson D, McEwan AJ, Riauka TA., Chest X-ray Artifact Caused by Bilateral 99mTc-Antimony Trisulfite Injection for Sentinel Node Imaging in a Patient With Breast Cancer. CLIN NUCL MED. Apr 2016; (41):319-320
  17. Makis W, McCann K, McEwan AJ, Sawyer MB., Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation., Clin Nucl Med. 2016 Mar;41(3):204-6. doi: 10.1097/RLU.0000000000000973.
  18. Makis W, McCann K, McEwan AJ, Sawyer MB., Palliation of Extensive Metastatic Bone Disease With 223Ra-Dichloride α-Particle Therapy in a Patient With Malignant Hereditary Paraganglioma-Pheochromocytoma Syndrome With SDHB Mutation., Clin Nucl Med. 2016 Feb;41(2):144-7. doi: 10.1097/RLU.0000000000000964.
  19. Makis W, McCann K, Riauka TA, McEwan AJ., Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy., Clin Nucl Med. 2016 Jan;41(1):50-2. doi: 10.1097/RLU.0000000000000971.
  20. Makis W, McCann K, McEwan AJ., Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol., Clin Nucl Med. 2016 Jan;41(1):53-4. doi:10.1097/RLU.0000000000001023.
  21. Makis W, McCann K, McEwan AJ. Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance. Peptide Receptor Radionuclide Therapy: A Suggested Protocol. Clin Nucl Med. Jan 2016; 41 (1):53-4. PubMed PMID: 26562579
  22. Makis W, McCann K, McEwan AJ, Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.  Clin Nucl Med. 2016 Feb;41(2):137-41.; PubMed PMID: 26447382
  23. Makis W, McCann K, McEwan AJ, Sawyer MB, Combined Treatment with 131I-MIBG and Sunitinib Induces Remission in a Patient with Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome from an SDHB Mutation. Clin Nucl Med. 2016 Mar;41(3):204-6.; PubMed PMID: 26359568
  24. Makis W, McCann K, Bryanton M, McEwan AJ, Cardiac Metastases of Neuroendocrine Tumors Treated With 177Lu DOTATATE Peptide Receptor Radionuclide Therapy or 131I-MIBG Therapy. Clin Nucl Med. Sept 2015, 40(12):962-964, PubMed PMID: 26359563
  25. Makis W, Robinson D, McEwan AJ, Riauka TA. Chest X-ray Artifact Caused by Bilateral 99mTc-AntimonyTrisulfite Injection for Sentinel Node Imaging in a Patient with Breast Cancer. Clin Nucl Med. Sept 2015, 41:(4)319-20;. PubMed PMID: 26359561
  26. Makis W, McCann K, Riauka TA, McEwan AJ, Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia with 177Lu- DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient with Pancreatic Neuroendocrine Tumor. Clin Nuc Med. Nov 2015;40 (11):880-4. PubMed PMID: 26359564

  27. Makis W., McCann K., McEwan AJB., The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols. Nucl. Med. Mol. Imaging, 2015, Mar; (49)223: 1869-3474. DOI: 10.1007/s13139-015-0332-6.

  28. Makis W., McCann K., Raiuka T., McEwan AJB., Glucagonoma Pancreatic Neuroendocrint Tumor Treated with 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Thearpy., Clin Nucl Med. 2015 Nov; 40(11):877-9.
  29. Niedermoser S, Chin J, Wangler C, Kostikov A, Bernard-Gauthier V, Vogler N, Soucy JP, McEwan AJ, Schirrmacher R, Wangler B., In Vivo Evaluation of 18F-AiFAlin-Modified TATE: A Potential Challenge for 68Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET., J Nucl Med. 2015 Jul;56(7):1100-5.
  30. O. Boychak, L.J. Vos, W. Makis, F.-A. Buteau, N. Pervez, M. Parliament, A.J.B. McEwan, N. Usmani, Role for 11-C-Choline PET in Active Surveillance of Prostate Cancer.,Can. Urol. Assoc. J, 2015 Mar. 9(3-4): e98-103.
  31. Makis W, McCann K, McEwan AJ, Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT., Clin Nucl Med. 2015 May;40(5)e278-81.
  32. Siu-Chu Q, Sangha R, Spratlin J, Vos L., Mackey J, McEwan AJB, Venner P, Michelakis E, A Phase I Open-Labeled, Single-Arm, Dose-Escalation, Study of Dicholoracetate (DCA) in Patients with Advanced Solid Tumors. Invest New Drugs., 2015 Jun;33(3):603-10., DOI: 10.1007/s10637-015-0221-y.
  33. Makis W, McCann K, McEwan AJB, Incidental Acini Cell Carcinoma of the Parotid Gland Dicordant on 123I-MIBG, 111ln-Octreotide, and 18F-FDG PET/CT in a Patient with Neuroendcorine Tumor of the Cecum., Clin Nucl Med. 2015 Aug;40(8):676-8.
  34. Makis W McCann K, McEwan AJB, Medullary Thyroid Carcinoma (MTC) treated with 177Lu-DOTATATE PRRT:a report of two cases., Clin Nucl Med. 2015 May; 40(5):408-12.
  35. Makis W, McCann K, McEwan AJB, Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-Octreotide and 177Lu-DOTATATE PRRT., Clin Nucl Med. 2015 Apr 40(4):317-21.
  36. Bouvet V, Jans HS, Wuest M, Soueidan OM, Grant T, Mercer J, McEwan AJ, West FG, Cheeseman CI, Wuest F, Erratum: Automated synthesis and dosimetry of 6-deoxy-6-[18F]fluoro-D-fructose (6-[18F]FDF): a radiotracer for imaging of GLUT5 in breast cancer., AM J Nucl Med Mol Imaging. 2014 Dec 15;5(1):95.
  37. Makis W, McCann K, McEwan AJB, Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT., Clin Nucl Med. 2015 Mar;40(3):237-40.
  38. Makis W, McCann K, McEwan AJB, Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies., Clin Nucl Med. 2015 Mar 40(3):234-6.
  39. Makis W., McCann K., Buteau FA, McEwan AJB, Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy., Clin Nucl Med. 2015 Aug;40(8)663-6.
  40. Makis W., McCann K., Buteau FA, McEwan AJB, Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy., Clin Nucl Med. 2015 Jul; 40(7):564-6.
  41. Makis W, McCann K, Buteau FA, McEwan AJB, Liver and Bone Metastases from Small Bowel Neuroendocrine Tumor Respond to 177Lu-Dotatate induction and maintenance therapies. Cln. Nucl. Med., 2015 Feb; 40(2):162-5. Doi:10.1097/RLU.0000000000000569.
  42. Aldawish M, Jha N, McEwan AJ, Severin D, Ghosh S, Morrish DW, Low but measurable stimulated serum thyroglobulin levels <2µg/L frequently predict incomplete response in differentiated thyroid cancer patients., Endocr Res. 2014;39(4):157-63.
  43. Swami VG, Joseph K, Hudson E, Usmani N, Tankel K, Severin D, Nijjar T, McEwan A, PDG Uptake pn PET/CT Can Assess Response to Chemoradiotherapy in Patinets with Anal Cancer., Pract Radiat Oncol. 2013 Apr-Jun; 3(2 Suppl 1):S28.
  44. McEwan AJB. The Leading Edge of Nuclear Medicine. International Innovation. 2013; 30-33.
  45. Amanie J, Jans HS, Wuest M, Pervez N, Murtha A, Usmani N, Yee D, Pearcey R, Danielson B, Patel S, Macewan R, Field C, Robinson D, Wilson J, Lewis D, Parliament M, McEwan AJ., Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy., Curr Oncol; 2013;20(2): (104-10).
  46. Mercer JR, McEwan AJ, Wiebe LI., [131I]IAZA as a molecular radiotherapeutic (MRT) drug: wash-out with cold IAZA accelerates clearance in a murine tumor model., Curr Radiopharm., 2013: 6(2): (87-91).
  47. Roa WH, Yaremko B, McEwan A, Amanie J, Yee D, Cho J, McQuarrie S, Riauka T, Sloboda R, Wiebe L, Loebenberg R, Janicki C. Dosimetry Study of [I-131] and [I-125]- Meta-Iodobenzyl Guanidine in a Simulating Model for Neuroblastoma Metastasis. Technol Cancer Res Treat. 2013;12(1):79-90
  48. Vickers MM, Pasieka J, Dixon E, McEwan S, McKay A, Renouf D, Schellenberg D, Ruether D. Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference: Calgary, Alberta Sept 8 - 10, 2011. Curr. Oncol. 2012;19(6)e-468-477
  49. Gagnon K, Wilson JS, Holt CM, Abrams DN, McEwan AJ, Mitlin D, McQuarrie SA. Cyclotron Production of 99mTc: recycling of enriched 100Mo Metal Targets. Applide Radiat. Isot. 2012;84(2):437-42
  50. Jha N, Harris J, Seikaly H, Jacobs JR, McEwan AJ, Robbins KT, Grecula J, Sharma AK, Ang KK. A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244). Int J Radiat Oncol Biol Phys. 2012;84(2):(437-42)
  51. AA El-Mabhouh, PN Nation, JT Abele, T Riauka, E. Postema, McEwan AJB, JR Mercer. A Conjugate of Gemcitabine with Bisphosphonate (Gem/BP) Shows Potential as a Targeted Bone-Specific Therapeutic Agent in an Animal Model of Human Breast Cancer Bone Metastases. Onc. Res., 2011; Vol 9:1-100.
  52. Wuest M, Trayner BJ, Grant TN, Jans HS, Mercer JR, Murray D, West FG, McEwan AJB, Wuest F, Cheeseman CI. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Nucl Med Biol. May 2011;38(4):(461-75).
  53. Gagnon K, McQuarrie S, Abrams D, McEwan AJB, Wuest F. Radiotracers Based on Technetium-94m Current Radiopharmaceuticals. 2011;4:(90-101)
  54. Kerhet A, Small C, Quon H, Riauka T, Schrader L, Greiner R, Yee D, McEwan A, Roa W. Application of Machine Learning Methodology for PET-Based Definition of Lung Cancer. Current Oncology, 2010, 17(1): 41-43.
  55. Kumar P, Naimi E, McEwan AJ, Wiebe LI. Synthesis, Radiofluorination, and Hypoxia-selective Studies of FRAZ: A Configurational and Positional Analogue of the Clinical Hypoxia Marker [18F]-FAZA. Bioorg Med Chem, 2010; 18(6):2255-2264.
  56. Paproski RJ, Wuest M, Jans HS, Graham K, Gati WP, McQuarrie S, McEwan A, Mercer J, Young JD, Cass CE. Biodistribution and uptake of 3’-deoxy-3’-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med, 2010; 51(9):1447-55.
  57. Graham MM and McEwan AJB. Therapeutic Pharmaceutical Developers Join with SNM and Molecular Imaging via the Clinical Trials Network. MI Gateway—Newsletter of the Society of Nuclear Medicine Molecular Imaging Center of Excellence, 2009; Special Issues: 1-5.
  58. Christian PE, Graham MM, McEwan AJB. The Phantom Program—A Roundtable Discussion with Paul Christian, Michael Graham and Alexander McEwan. MI Gateway—Newsletter of the Society of Nuclear Medicine Molecular Imaging Center of Excellence, 2009; Special Issues: 4-5.
  59. Suchak AA, Millo N, MacEwan R, McEwan AJB. Neuroendocrine Differentiated Breast Carcinoma with Pleural Metastases Using Indium-111 Octreotide. Clin Nucl Med, 2009; 34:74-75.
  60. McEwan A, Graham MM, Conti PS. SNM Newsline: SNM Molecular Imaging Summit Introduces Clinical Trials Network. J Nucl Med, 2009; 50(4):18N.
  61. Postema EJ, McEwan AJB, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. Initial Results of Hypoxia Imaging Using 1--D-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging, 2009; 36: 1565-1573.
  62. Postema EJ and McEwan AJB. Radioiodinated Metaiodobenzylguanidine Treatment of Neuroendocrine Tumors in Adults. Cancer Biotherapy and Radiopharmaceuticals, 2009; 24(5): 519-525.
  63. Kumar P, Emami S, Kresolek Z, Yang J, McEwan AJ, Wiebe LI. Synthesis and hypoxia selective radiosensitization potential of beta-2-FAZA and beta-3-FAZL: fluorinated azomycin beta-nucleosides. Med Chem, 2009; 5(2):118-129.
  64. McEwan AJB, Graham MM, Conti PS. Site Qualification in Multicenter Clinical Trials. J Nucl Med, 2009; 50(8): 30N.
  65. McEwan AJB. Continuing and Accumulating Successes. J. Nucl Med 2008; 49(2): 16N-18N.
  66. Kumar P, Emami S, McEwan AJB, Wiebe LI. Stereospecific deuteration of furanosyl azomycin nucleosides; a model reaction for tritium radiolabeling. Bioorganic & Medicinal Chemistry Letters, 2008; 18(11):3256-3260.
  67. McEwan AJB, Van Brocklin HF, Divgi C. Action Plan for Emerging Molecular Imaging Technologies. JNM White Paper. J Nucl Med 2008; 49(2):37N-41N.
  68. Sangha GS, Severin D, Postema E, McEwan A, Stewart K. Is positron emission tomography useful in locoregional staging of esophageal cancer? Results of a multidisciplinary initiative comparing CT, positron emission tomography and EUS. Gastrointest Endosc, 2008; 67(3):402-409.
  69. McEwan AJB. SNM Leadership Update: A Look Back at a Year of Extraordinary Success and Forward to a Rewarding Future. J Nucl Med, 2008; 49(6): 80N-81N.
  70. Conti PS, McEwan AJB, Pomper MG. SNM Newsline: Molecular Imaging: The Future of Modern Medicine. J Nucl Med, 2008; 49(6):16N-20N.
  71. Kong T, Zeng J, Wang X, Yang X, Yang J, McQuarrie S, McEwan A, Roa W, Chen J, Xing JZ. Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles. Small, 2008; 4(9):1537-1543.
  72. Sharma SK, Zheng W, Joshua AV, Abrams DN, McEwan AJB. Synthesis and Evaluation of Novel 4-amino-4,6-androstadiene-3,17-dione: An Analog of Formestane. Bioorganic & Medicinal Chemistry Letters, 2008; 18(20): 5563-5566.
  73. Murray D and McEwan AJ. Radiobiology of Systemic Radiation Therapy. Cancer Biotherapy and Radiopharmaceuticals 2007, 22(1):1-23.
  74. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JA, Coldwell D. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 (Y90) Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Rad Oncol Biol Phys 2007; 68(1):13-23.
  75. Demeter S, Jacobs P, Chmielowiec C, Logus W, Hailey D, Fassbender K, McEwan AB. The Cost of Lung Cancer in Alberta. Can Resp J 2007; 14(2):81-86.
  76. Joshua A, Sharma SK, Strelkov A, Scott JR, Martin-Iverson MT, Abrams DN, Silverstone PH, McEwan AJB. Synthesis and Biodistribution of 8-Iodo-11-(4-methylpiperazino)-5H-dibenzo[b,e][1,4]-diazepine: Iozapine. Bioorg Med Chem Lett 2007; 17: 4066-4069.
  77. Drever L, Roa W, McEwan A, Robinson D. Comparison of three image segmentation techniques for target volume delineation in positron emission tomography. J Appl Clin Med Phys 2007; 8(2): 93-109.
  78. Drever L, Roa W, McEwan A, Robinson D. Iterative threshold segmentation for PET target volume delineation. Med Phys 2007; 34(4): 1253-1265.
  79. McEwan AJB. SNM Leadership Update: Molecular Imaging…Realistically…An Evolution in Nuclear Medicine Practice. J Nucl Med, 2007; 48(8): 31N, 38N.
  80. McEwan AJB. How Do We Introduce the Next Generation of Radiotracers into Clinical Practice? SNM Leadership Update, J Nucl Med, 2007; 48(9): 28N, 30N.
  81. Kumar P, Mercer, J, Doerksen C, Tonkin K, McEwan AJB. Clinical production, stability studies and PET imaging with 16-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J Pharm Pharmaceut Sci, 2007; 10(2); 256s-265s.
  82.  Emami S, Kumar P, Yang J, Kresolek Z, Paproski R, Cass C, McEwan AJB, Wiebe LI. Synthesis, transport and hypoxia-selective binding of 1--D-(5-deoxy-5-fluororibofuranosyl)-2-nitroimidazole (-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. J Pharm Pharmaceut Sci, 2007; 10(2): 237-245.
  83. McEwan AJB. SNM Leadership Update: Funding Nuclear Medicine Research. J Nucl Med, 2007; 48(11); 23N.
  84. McEwan AJB. Radiation Rules are Strict. Letter. USA Today, November 28, 2007.
  85. McEwan AJB. SNM Leadership Update: Advocating for PET/CT. J Nucl Med, 2007; 48(12): 26N.
  86. Drever L, Robinson DM, McEwan AJB, Roa W. A Local Contrast Based Approach to Threshold Segmentation for PET Target Volume Delineation. Medical Physics 2006; 33(6):1583-1594.
  87. Gulenchyn KY, McEwan AJ, Freeman M, Kiess M, O'Neill BJ, Beanlands RS, CANM, CSS. Treating the right patient at the right time: access to cardiovascular nuclear imaging. Can J Cardiol 2006; 22(1):827-833.
  88. Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B, Riauka T, Hanson J. Fulton D, McEwan A, Roa W. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006; 29(5):301-311.
  89. Sandler MP, McEwan AJ. Revolutionizing the Future. RT Image 2006; 19(45). (www.rt-image.com.)
  90. Piert M, Machulla H-J, Picchio M, Reischl G, Ziegler S, Kumar P, Wester H-J, Beck R, McEwan AJB, Wiebe LI, Schwaiger M. Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside. J Nucl Med 2005; 46: 106-113.
  91. Yaremko B, Riauka T, Robinson D, Murray B, McEwan A, Roa W. Threshold Modification for Tumour Imaging in Non-Small-Cell Lung Cancer Using Positron Emission Tomography.  Nuc Med Commun 2005; 26(5): 433-440.
  92. Chuck A, Jacobs P, Logus JW, St. Hilaire D, Chmielowiec C, McEwan AJB. Marginal Cost of Operating a Positron Emission Tomography Center in a Regulatory Environment. Int J Technol Assess Health Care 2005; 21(4):422-451.
  93. Kumar P, McQuarrie SA, Zhou A, McEwan AJB, Wiebe LI. [131I]Iodoazomycin arabinoside for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice. Nucl Med Biol 2005; 32(6):647-653.
  94. Morin KW, Duan W, Knaus EE, McEwan AJB, Wiebe LI. A Human Osteosarcoma Cell Line Expressing Herpes Simplex Type-1 Thymidine Kinase: Studies with Radiolabeled (E)-5-(2-iodovinyl)-2’-fluoro-2’-deoxyuridine. Nucl Med Biol 2005; 32(5):459-464.
  95. Naimi E, Kumar P, McEwan AJB, Wiebe LI. A one-pot synthesis of 1-alpha- and 1-beta-D-arabinofuranosyl-2-nitroimidazoles: Synthons to the Markers of Tumor Hypoxia. Nucleosides Nucleotides Nucleic Acids 2005; 24(3):173-178.
  96. Yaremko B, Riauka T, Robinson D, Murray B, Alexander A, McEwan AJB, Roa W. Thresholding in PET images of static and moving targets. Phys Med Biol 2005; 50:1-14.
  97. McEwan AJB. Does Health Technology Assessment Put Patient Care at Risk? (Comment) J Nucl Med 2005; 46(12): 1939.
  98. Morin KW, Duan W, Xu L, Zhou A, Moharram S, Knaus EE, McEwan AJB, Wiebe LI. Cytotoxicity and Cellular Uptake of Pyrimidine Nucleosides for Imaging Herpes Simplex Type-1 Thymidine Kinase (HSV-1 TK) Expression in Mammalian Cells. Nucl Med Biol, 2004, 31(5):623-630.
  99. Paty BW, Bonner-Weir S, Laughlin, MR. McEwan AJ, Shapiro AM. Toward Development of Imaging Modalities for Islets after Transplantation: Insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation 2004; 77(8):1133-1137.
  100. Holloway CL, Robinson D, Murray B. Amanie J. Butts C, Smylie M. Chu K, McEwan AJB, Halperin R, Roa WH. Results of a Phase I Study to Dose Escalate Using Intensity Modulated Radiotherapy Guided by Combined PET/CT Imaging with Induction Chemotherapy for Patients with Non-Small Cell Lung Cancer. Radiother Oncol 2004; 73: 285-287.
  101. Sywak MS, Pasieka JL, McEwan AJB, Kline G, Rorstad O. 131I-Meta-iodobenzylguanidine in the Management of Metastatic Midgut Carcinoid Tumors. World J Surg 2004; 28: 1157-1162.
  102. El-Mabhouh A, Angelov C, McEwan A, Jia G, Mercer J. Preclinical Investigations of Drug and Radionuclide Conjugates of Bisphosphonates for the Treatment of Metastatic Bone Cancer. Cancer Biotherapy & Radiopharmaceuticals 2004; 19(5): 627-640.
  103. Pasieka JK, McEwan AJB, Rorstad O. The palliative role of 131I-MIBG and 111In-Octreotide Therapy in Patients with Metastatic Progressive Neuroendocrine Neoplasms. Surgery. 2004; 136(6):1218-1226.
  104. Demeter S, Chmielowiec C, Logus W, Benkovska-Angelova P, Jacobs P, Hailey D, McEwan AJB. The Descriptive Epidemiology of Primary Lung Cancer in an Alberta Cohort with a Multivariate Analysis of Survival to Two Years. Can Resp J 2003;10(8):435-441.
  105. McEwan AJB. Radioisotope Therapy and Clinical Trial Design: The Need for Consensus and Innovation. Invited Commentary. J Nucl Med 2002; 43(1): 87-88.
  106. Angelov CM, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 3-Methyl-1,2-butadienyl-1,1-diphosphonate(1-). Acta Crystallographica 2002; E58: o498-o500.
  107. Angelov CM, Mazzuca DA, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 2-(3-Methyl-1,2-butadienyl)-2-oxo-1,3,2-oxazaphosphorinane. Acta Crystallographica 2002; E58: o399-o401.
  108. Wiebe LI and McEwan AJB. Scintigraphic Imaging of Focal Hypoxic Tissue: Development and Clinical Applications of 123I-IAZA. Brazilian Archives of Biology and Technology, 2002; 45 (Special n):69-81.
  109. Kumar P, Wiebe LI, Mannan RH, Zhang Z, Xia H, McEwan AJB. [99mTc]Technetium labelled PnAo-azomycin Glucuronides: A Novel Class of Imaging Markers of Tissue Hypoxia. Applied Radiation and Isotopes 2002; 57: 719-728.
  110. Kumar P, Wiebe LI, Asikoglu M, Tandon M, McEwan AJB. Microwave-assisted (Radio) halogenation of Nitroimidazole-based Hypoxia Markers. Applied Radiation and Isotopes 2002, 57; 697-703.
  111. Pasieka JL, McKinnon JG, Kinnear S, Yelle CA, Numerow L, Paterson A, Rorstad O, DiFrancesco LM, McEwan A, Skogseid B. Carcinoid Syndrome Symposium on Treatment Modalities for Gastrointestinal Carcinoid Tumours: Symposium Summary. Can J Surg 2001; 44(1): 25-32.
  112. Morin KW, Duan W, Knaus EE, McEwan AJB, Wiebe LI. A Human Osteosarcoma Cell Line Expressing Herpes Simplex Type-1 Thymidine Kinase: Studies with Radiolabeled (E)-5-(2-iodovinyl)-2’-fluoro-2’-deoxyuridine. Nucl Med Biol 2005; 32(5):459-464.
  113. Naimi E, Kumar P, McEwan AJB, Wiebe LI. A one-pot synthesis of 1-alpha- and 1-beta-D-arabinofuranosyl-2-nitroimidazoles: Synthons to the Markers of Tumor Hypoxia. Nucleosides Nucleotides Nucleic Acids 2005; 24(3):173-178.
  114. Yaremko B, Riauka T, Robinson D, Murray B, Alexander A, McEwan AJB, Roa W. Thresholding in PET images of static and moving targets. Phys Med Biol 2005; 50:1-14.
  115. McEwan AJB. Does Health Technology Assessment Put Patient Care at Risk? (Comment) J Nucl Med 2005; 46(12): 1939.
  116. Morin KW, Duan W, Xu L, Zhou A, Moharram S, Knaus EE, McEwan AJB, Wiebe LI. Cytotoxicity and Cellular Uptake of Pyrimidine Nucleosides for Imaging Herpes Simplex Type-1 Thymidine Kinase (HSV-1 TK) Expression in Mammalian Cells. Nucl Med Biol, 2004, 31(5):623-630.
  117. Paty BW, Bonner-Weir S, Laughlin, MR. McEwan AJ, Shapiro AM. Toward Development of Imaging Modalities for Islets after Transplantation: Insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation 2004; 77(8):1133-1137.
  118. Holloway CL, Robinson D, Murray B. Amanie J. Butts C, Smylie M. Chu K, McEwan AJB, Halperin R, Roa WH. Results of a Phase I Study to Dose Escalate Using Intensity Modulated Radiotherapy Guided by Combined PET/CT Imaging with Induction Chemotherapy for Patients with Non-Small Cell Lung Cancer. Radiother Oncol 2004; 73: 285-287.
  119. Sywak MS, Pasieka JL, McEwan AJB, Kline G, Rorstad O. 131I-Meta-iodobenzylguanidine in the Management of Metastatic Midgut Carcinoid Tumors. World J Surg 2004; 28: 1157-1162.
  120. El-Mabhouh A, Angelov C, McEwan A, Jia G, Mercer J. Preclinical Investigations of Drug and Radionuclide Conjugates of Bisphosphonates for the Treatment of Metastatic Bone Cancer. Cancer Biotherapy & Radiopharmaceuticals 2004; 19(5): 627-640.
  121. Pasieka JK, McEwan AJB, Rorstad O. The palliative role of 131I-MIBG and 111In-Octreotide Therapy in Patients with Metastatic Progressive Neuroendocrine Neoplasms. Surgery. 2004; 136(6):1218-1226.
  122. Demeter S, Chmielowiec C, Logus W, Benkovska-Angelova P, Jacobs P, Hailey D, McEwan AJB. The Descriptive Epidemiology of Primary Lung Cancer in an Alberta Cohort with a Multivariate Analysis of Survival to Two Years. Can Resp J 2003;10(8):435-441.
  123. McEwan AJB. Radioisotope Therapy and Clinical Trial Design: The Need for Consensus and Innovation. Invited Commentary. J Nucl Med 2002; 43(1): 87-88.
  124. Angelov CM, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 3-Methyl-1,2-butadienyl-1,1-diphosphonate(1-). Acta Crystallographica 2002; E58: o498-o500.
  125. Angelov CM, Mazzuca DA, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 2-(3-Methyl-1,2-butadienyl)-2-oxo-1,3,2-oxazaphosphorinane. Acta Crystallographica 2002; E58: o399-o401.
  126. Wiebe LI and McEwan AJB. Scintigraphic Imaging of Focal Hypoxic Tissue: Development and Clinical Applications of 123I-IAZA. Brazilian Archives of Biology and Technology, 2002; 45 (Special n):69-81.
  127. Kumar P, Wiebe LI, Mannan RH, Zhang Z, Xia H, McEwan AJB. [99mTc]Technetium labelled PnAo-azomycin Glucuronides: A Novel Class of Imaging Markers of Tissue Hypoxia. Applied Radiation and Isotopes 2002; 57: 719-728.
  128. Kumar P, Wiebe LI, Asikoglu M, Tandon M, McEwan AJB. Microwave-assisted (Radio) halogenation of Nitroimidazole-based Hypoxia Markers. Applied Radiation and Isotopes 2002, 57; 697-703.
  129. Pasieka JL, McKinnon JG, Kinnear S, Yelle CA, Numerow L, Paterson A, Rorstad O, DiFrancesco LM, McEwan A, Skogseid B. Carcinoid Syndrome Symposium on Treatment Modalities for Gastrointestinal Carcinoid Tumours: Symposium Summary. Can J Surg 2001; 44(1): 25-32.
  130. Salopek TG, Scott JR, Joshua AV, Smylie M, Logus JW, Morin CA, McEwan AJB. Radioiodinated N-[3-(4-Morpholino)Propyl]-N-Methyl-2-Hydroxy-5-Iodo-3-Methyl-benzylamine (ERC9): A New Potential Melanoma Imaging Agent. Eur J Nucl Med 2001; 28 (4): 408-417.
  131. Stypinski D, McQuarrie SA, Wiebe LI, Tam YK, Mercer JR, McEwan AJB. Pharmacokinetic Estimations for 123I-IAZA in Healthy Volunteers. J Nucl Med 2001; 42(9):1418-1423.
  132. Lee HC, Kumar P, McEwan AJB, Wiebe LI, Mercer JR. Synthesis, Radiolabelling and Biodistribution of Putative Metabolites of Iodoazomycin Arabinoside (IAZA). Nucl Med Biol 2000; 27(1): 61-68.
  133. Morin KW, Knaus EE, Wiebe LI, Xia H, McEwan AJB. Reporter Gene Imaging: Effects of Ganciclovir Treatment on Nucleoside Uptake, Hypoxia and Perfusion in a Murine Gene Therapy Tumour Model that Expresses Herpes Simplex Type-1 Thymidine Kinase. Nucl Med Commun 2000; 21: 129-137.
  134. McEwan AJB. Use of Radionuclides for the Palliation of Bone Metastases. Semin Radiat Oncol 2000; 10(2): 103-114.
  135. Kumar P, Stypinski D, Xia H, McEwan AJB, Machulla H-J, Wiebe LI. Fluoroazomycin Arabinoside (FAZA): Synthesis, 2H and 3H-labelling and Preliminary Biological Evaluation of a Novel 2-Nitroimidazole Marker of Tissue Hypoxia. J Lab Comp Radiopharmaceuticals 1999; 42:3-16.
  136. Lythgoe MF, Williams SR, Busza AL, Wiebe L, McEwan AJB, Gadian DG, Gordon I. The Relationship Between Magnetic Resonance Diffusion Imaging and Autoradiographic Markers of Cerebral Blood Flow and Hypoxia in an Animal Stroke Model. J Magnetic Resonance in Medicine 1999; 41:706-714.
  137. Stypinski D, Wiebe LI, McEwan AJB, Schmidt RP, Tam YK, Mercer JR. Clinical Pharmacokinetics of 123I-IAZA in Healthy Volunteers. Nucl Med Commun 1999; 20: 559-567.
  138. Vinjamuri S, O’Driscoll K, Maltby P, McEwan AJB, Wiebe LI, Critchley M. Identification of Hypoxic Regions in Traumatic Brain Injury. Clin Nucl Med 1999; 24(11): 891-892.
  139. Roa WHY, Miller GG, McEwan AJB, McQuarrie SA, Tse JC, Wu J, Wiebe LI. Targetted Radiotherapy of Multicell Neuroblastoma Spheroids with High Specific Activity [123I]meta-iodobenzylguanidine. Int J Radiat Oncol Biol Phys 1998; 41(2): 425-432.
  140. McQuarrie SA, Riauka T, Baum RP, Sykes TR, Boniface G, MacLean GD, Noujaim AA, McEwan AJB. The Effects of Circulating Antigen on the Pharmacokinetics and Radioimmunoscintigraphic Properties of 99mTc Labelled Monoclonal Antibodies in Cancer Patients. J Pharm and Pharmaceutical Sciences 1998; 1(3): 115-125.
  141. McEwan AJB. Palliative Therapy with Bone Seeking Radiopharmaceuticals. Cancer Biotherapy & Radiopharmaceuticals 1998; 13(6): 413-426.
  142. Johnson MA, Davis P, McEwan AJB, Jhangri GS, Warshawski R, Gargum Ali, Ethier J, Anderson WW. Preliminary Findings from a Teleultrasound Study in Alberta. Telemedicine Journal 1998; 4(3): 267-276.
  143. Lythgoe MF, Williams SR, Wiebe LI, McEwan AJB, Gordon I. Autoradiographic Imaging of Cerebral Ischaemia Using a Combination of Blood Flow and Hypoxic Markers in an Animal Model. Eur J Nucl Med 1997; 24 (1): 16-20.
  144. Tibbo P, Silverstone PH, McEwan AJB, Scott J, Joshua A, Golberg K. A Single Photon Emission Computed Tomography Scan Study of Striatal Dopamine D2 Receptor Binding with 123I-Epidepride in Schizophrenic Patients and Controls. J Psychiatry and Neurosci 1997; 22 (1):39-45.
  145. McQuarrie SA, MacLean GD, Boniface GR, Golberg K, McEwan AJB. Radioimmunoscintigraphy in Patients with Breast Adenocarcinoma Using 99mTc Labelled Monoclonal Antibody 170H.82 -- Report of  Phase II Study. Eur J Nucl Med 1997; 24: 381-389.
  146. McEwan AJB. Unsealed Source Therapy of Painful Bone Metastases: An Update. Semin Nucl Med, 1997; 23 (2): 165-182.
  147. Okarvi SM, Angelov CM, Cavell RG, McEwan AJB, Suresh MR. Radiolabelling Characteristics of Novel Iminophosphorane Ligands with Technetium-99m. J Labelled Compounds and Radiopharmaceuticals, J Labelled Compounds Radiopharm, 1997; 39(10): 833-851.
  148. McQuarrie SA, Baum RP, Niesen A, Madiyalakan R, Korz W, Sykes TR, Sykes CJ, Hör G, McEwan AJB, Noujaim AA. Pharmacokinetics and Radiation Dosimetry of 99Tcm-labelled Monoclonal Antibody B43.13 in Ovarian Cancer Patients. Nucl Med Commun, 1997; 18: 878-886.
  149. Dessureault S, Koven R, Reilly RM, Couture J, Schmocker B, Damani M, Kirsh J, Ichise M, Sidlofsky S, McEwan AJB, Boniface G, Stern H, Gallinger S. Pre-operative Assessment of Axillary Lymph Node Status in Patients with Breast Adenocarcinoma Using Intravenous 99mTechnetium mAb-170H.82 (Tru-Scint®AD™). Breast Cancer Research and Treatment 1997; 45: 29-37.
  150. Urtasun RC, Parliament MB, McEwan AJ, Mercer JR, Mannan RH, Wiebe LI, Morin C, Chapman JD. Measurement of Hypoxia in Human Tumors by Non-Invasive SPECT Imaging of Iodoazomycin Arabinoside. Br J Cancer, 1996; 74 (Suppl. 27): S209-S212.
  151. Carson BJW, McEwan AJB, Hoskinson ME, Maguire CG. Detection of an Abdominal Mycotic Aneurysm on Three-Phase Bone Scan: A Case Report. Clin Nucl Med 1995; 20(3): 267-269.
  152. Martin WRW, Hoskinson M, Kremer B, Maguire C, McEwan AJB. Functional Caudate Imaging in Symptomatic Huntington’s Disease: Positron Emission Tomography versus Single-Photon Emission Computed Tomography. J Neuroimag 1995; 5: 227-232.
  153. Griffiths DJ, McCracken PN, Harrison GM, Gormley EA, Moore K, Hooper R, McEwan AJB, Triscott J. Cerebral aetiology of urinary urge incontinence in the elderly. Age and Aging 1994; 23: 236-250.
  154. McEwan AJB, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A Retrospective Analysis of the Cost Effectiveness of Treatment with Metastron (Strontium-89 Chloride) in Patients with Prostate Cancer Metastatic to Bone. Nuc Med Commun 1994; 15: 499-504.
  155. McQuarrie SA, Baum RP, Golberg L, Niesen A, Golberg K, Noujaim AA, McEwan AJB. A Pharmacokinetic Comparison of Murine and Chimeric Forms of the 99mTc Labelled 174H.64 Monoclonal Antibody. J Nucl Biol Med 1994;38 (Suppl. 1 to No. 4):140-144.
  156. Al-Arafaj A, Ryan EA, Hutchison K, Mannan RH, Mercer J, Wiebe LI, McEwan AJB. An Evaluation of 123I-Iodoazomycinarabinoside ([123I]-IAZA) as a Marker of Localized Tissue Hypoxia in Patients with Diabetes Mellitus. Eur J Nucl Med 1994; 21: 1338-1342.
  157. Dawson MRW, Dobbs A, Hooper HR, McEwan AJB, Triscott J, Cooney J. Artificial Neural Networks that Use Single-Photon Emission Tomography to Identify Patients with Probable Alzheimer’s Disease. Eur J Nucl Med 1994; 21: 1303-1311.
  158. McEwan AJB, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A Retrospective Analysis of the Cost Effectiveness of Treatment with Metastron in Patients with Prostate Cancer Metastatic to Bone. Eur Urol 1994; 26 (Suppl 1): 26-31.
  159. McEwan AJB. Pain palliation and nuclear medicine. (Editorial) Eur J Nuc Med, 1993; 20: 1-3.
  160. Moore RB, Chapman JD, Mercer JR, Mannan RH, Wiebe LI, McEwan AJB, McPhee MS. Measurement of PDT-induced hypoxia in the Dunning prostate tumors by Iodine-123-iodoazomycin arabinoside. J Nuc Med, 1993; 34:405-413.
  161. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J. Gulenchyn KY, Hong KE, Wesolowski C, Yardley J. Results of a randomized phase III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiation Oncology Biol Phys, 1993; 25: 805-813.
  162. Adams BL, Warneke LB, McEwan AJB, Fraser BA. Single Photon Emission Computerized Tomography in Obsessive Compulsive Disorder: A Preliminary Study. J Psychiatri Neurosci, 1993; 18, 3: 109-112.
  163. Groshar D, McEwan AJB, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, Mercer JR, Mannan RH, Wiebe LI, Chapman JD. Imaging tumor hypoxia and tumor perfusion. J Nuc Med, 1993; 34: 885-888. (Manuscript received the Journal of Nuclear Medicine Manuscript of the Year Award for 1993).
  164. Porter AT, McEwan AJB. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled study. Seminars in Oncology, 1993; 20 (3, Suppl 2): 38-43.
  165. Ignaszewski AP, McCormick LX, Heslip PG, McEwan AJB, Humen DP. Safety and Clinical Utility of Combined Intranvenous Dipyridamole/Symptom-Limited Exercise Stress Test with Thallium-201 Imaging in Patients with Known or Suspected Coronary Artery Disease. J Nucl Med 1993; 34: 2053-2061.
  166. McEwan AJB, MacLean GD, Hooper HR, Sykes T, McQuarrie SA, Golberg L, Bodnar DM, Lloyd SL, Noujaim AA. MAb 170H.82: An Evaluation of a novel panadenocarcinoma monoclonal antibody labelled with Technetium-99m and with Indium-111. Nuc Med Commun, 1992; 13: 11-19.
  167. Parliament MB, Chapman JD, Urtasun RC, McEwan AJB, Golberg L, Mercer JR, Mannan RH, Wiebe LI. Non-invasive assessment of human tumour hypoxia with 123I-Iodoazomycin Arabinoside: Preliminary report of a clinical study. Br J Cancer, 1992; 65: 90-95.
  168. Jen H, Tracey K, Catz Z, McEwan AJB. Bone scan appearance of diastasis pubis in association with congenital extrophy of the bladder. Clin Nuc Med, 1992; 17:47.
  169. Moore RB, Chapman JD, Mokrzanowski AD, Arnfield MR, McPhee MS, McEwan AJB. Non-invasive monitoring of photodynamic therapy with 99mTechnetium HMPAO. Br J Cancer, 1992; 65:491-497.
  170. Champion PE, Groshar D, Hooper HR, Palmer M, Catz Z, Belch A, McEwan AJB. Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkin's lymphoma? Nuc Med Commun, 1992; 13:730-737.
  171. McEwan AJB, Jackson FI, Catz Z, Schmidt RP, Hooper HR, Matthews JJD. Tc-99m hexamethylpropyleneamine oxime (HMPAO) to demonstrate diffuse cortical necrosis in-vivo. Clin Nuc Med, 1991; 16,3: 167-169.
  172. MacLean GD, McEwan AJB, Noujaim AA, Hooper HR, Sykes TR, Bodnar DM, Lloyd S, Golberg LE, Longenecker BM. Two novel monoclonal antibodies have potential for gynecologic cancer imaging. Antibody, Immunoconjugates & Radiopharmaceuticals, 1991; 4,3: 297-308.
  173. Lewington VJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA, McEwan AJB. A prospective, randomised double-blind crossover study to examine the efficacy of Strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer, 1991; 27,8: 954-958.
  174. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJB, Macleod PA, Zivanovic MA. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Rad, 1991; 64: 816-822.
  175. Tracey KP, Jen H, Metcalfe JB, McEwan AJB. Case report: Autosomal recessive (infantile) polycystic kidney disease demonstrated by Tc-99m DMSA renal imaging. Clin Nuc Med, 1991; 16,11: 833-835.
  176. Lewington VJ, Zivanovic MA, Tristam M, McEwan AJB, Ackery DM. Radiolabelled Metaiodobenzylguanidine Targeted Radiotherapy for Malignant Phaeochromocytoma. J Nucl Biol Med, 1991; 35: 280-283.
  177. McEwan AJB, Porter AT, Venner PM, Amyotte G. An evaluation of the safety and efficacy of Treatment with Strontium-89 in Patients who have previously received wide field radiotherapy. Antibody, Immunoconjugates & Radiopharmaceuticals 1990; 3,2: 91-98.
  178. Hooper HR, McEwan AJB, Lentle BC, Kotchon TL, Hooper PM. Interactive three dimensional region of interest analysis of HM-PAO SPECT brain studies. J Nucl Med 1990; 31,12: 2046-2051.
  179. Morrish DW, Filipow JF, McEwan AJB, Schmidt R, Murland KR, von Westarp C, Betcher KB. 131I treatment of thyroid papillary carcinoma in a patient with renal failure. Cancer 1990; 66,12: 2509-2513
  180. Robinson RG, Blake GM, Preston DF, McEwan AJB, Spicer JA, Martin NL, Wegst AV, Ackery DM. Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989; 9: 271-281.
  181. MacLean GD, McEwan AJB, Noujaim AA, Sykes TR, Suresh MR, Catz Z, Hooper HR, Longenecker BM.  A novel strategy for cancer immunoscintigraphy. Antibody, Immunoconjugates and Radiopharmaceuticals 1989; 2: 15-27.
  182. Thompson JF, Clifford PC, McEwan AJB, Chant AD. Case Report: Phaeochromocytoma and Abdominal Aneurysm: Confirmation of Diagnosis after Aortic Surgery using mIBG Imaging. Eur J Vasc Surg 1989; 3: 457-459.
  183.  McQuarrie SA, Ung Y, McEwan AJB. 99mTc hexamethyl propyleneamine oxime (HMPAO)--an animal model of tumor perfusion. Proceedings of the International Association of Radiopharmacology 1989: 96-103.
  184. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJB, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 1988; 29: 549-557.
  185. Jha N, McEwan AJB. Distinguishing metastatic prostate cancer and Paget's disease. Diagnosis, June, 1988: 135-139.
  186. Blake GM, Zivanovic MA, McEwan AJB, Condon BR, Ackery DM. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma and neuroblastoma. Br J Radiol 1987; 60: 253-259.
  187. Von Moll L, McEwan AJB, Shapiro B, Sisson JC, Gross MD, Lloyd R, Beals E, Beierwaltes WH, Thomson NW. Iodine-131 mIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 1987; 28: 979-988.
  188. Blake GM, Zivanovic MA, McEwan AJB, Batty VB, Ackery DM. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med 1987; 13: 41-46.
  189. Blake GM, Gray JM, Zivanovic MA, McEwan AJB, Fleming JS, Ackery DM. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol 1987; 60: 685-692.
  190. Tippett PA, West RS, McEwan AJB, Ackery DM. A comparison of dopamine and homovanillic acid excretion, as prognostic indicators in malignant phaeochromocytoma. Clin Chem Acta 1987; 166: 123-133.
  191. McEwan AJB, Davis CL, Ackery DM. Bladder phaeochromocytoma diagnosed by radioiodinated meta iodobenzylguanidine imaging. Br J Urol 1987; 30: 594-595.
  192. McEwan AJB, Wyeth P, Ackery DM. Radioiodinated iodobenzylguanidines for diagnosis and therapy. Int J Appl Radia Isot 1986; 37: 767-775.
  193. Tippett PA, McEwan AJB, Ackery DM. A re-evaluation of dopamine excretion in phaeochromocytoma. Clin Endocrinol 1986; 25: 401-410.
  194. Blake GM, Zivanovic MA, McEwan AJB, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986; 12: 447-454.
  195. McEwan AJB, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radioiodobenzylguanidine for the scintigraphic localization and therapy of adrenergic tumors. Semin Nucl Med 1985; 15: 132-153.
  196. Paes RA, McEwan AJB, Ackery DM. Unilateral pulmonary blood flow loss in a young patient. Nucl Med Commun 1985; 6: 347-351.
  197. Macleod MA, McEwan AJB, Pearson RR, Houston AS. Functional imaging in the early diagnosis of dysbaric osteonecrosis. Br J Radiol 1982; 55: 497-500.
  198. Pearson RR, Macleod MA, McEwan AJB, Houston AS. Bone scintigraphy as an investigative aid for dysbaric osteonecrosis in divers. J R Med Serv 1982; 68: 61-68.
  199. Macleod MA, Pearson RR, McEwan AJB, Khan O. Bone scintigraphy in dysbaric related osteopathy. Nucl Med Commun 1981; 2: 235-241.
  200. Radiobiology as applied to radionuclide therapy with an emphasis on low dose rate radiation effects Murray D, Mirzayans R, McEwan AJB. In: Nuclear Medicine Therapy: Principles and Clnical Applications. Ed: C Aktolun and SJ Goldsmith, New York, 2013, pp 383-407.
  201. Palliation of Bone Pain. McEwan AJB. In: Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd edition. Ed: S. Gambhir and P. Ell, Churchill Livingstone, Edinburgh, 2004, pp 407-421.
  202. Bone Seeking Radiopharmaceuticals to Palliate Painful Bone Metastases. McEwan AJB. In: Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. Eds: C. Bountra, R. Munglani and W. Schmidt. Marcel Dekker, Inc., New York, 2003, pp 835-855.
  203. Tumor Imaging. McEwan AJB. In: Nuclear Medicine. Eds: W.D Leslie and I.D. Greenberg. Landes Bioscience, Texas, USA, 2003, pp 297-339.
  204. Pain from Metastatic Bone Tumors. McEwan AJB. In: Nuclear Oncology. Ed: W.N. Tauxe and C. Aktolun, Springer-Verlag, Heidelberg, 1999, pp 245-260.
  205. Synthesis, Radiochemical and Biological Evaluation of Novel 99mTc-Phosphorus-Nitrogen Complexes. Okarvi SM, Angelov CM, Cavell RG, Suresh MR, McEwan AJB. In: Technetium, rhenium and Other Metals in Chemistry and Nuclear Medicine. Eds: M Nicolini and U. Mazzi. SGE Editoriali, Italy, 1999, pp 447-455.
  206. Palliation of Bone Pain. McEwan AJB. In: Nuclear Medicine in Clinical Diagnosis and Treatment, 2nd edition. Ed: I.P.C. Murray and P. Ell, Churchill Livingstone, Edinburgh, 1998, pp 1083-1099.
  207. Development of a New Technetium Complex for Hypoxia Imaging: A Technetium (V) Amine Nitrophenol Complex. Zhang Z, Mannan RH, Wiebe LI, McEwan AJB. In: Technetium and Rhenium Chemistry and Nuclear Medicine, Eds: M. Nicolini, G. Bandoli and U. Mazzi, SGEditoriali, Padova, Italy, 1995, pp 307-312.
  208. Palliation of bone pain. McEwan AJB. In: Nuclear Medicine in Clinical Diagnosis and Treatment, ed: I.P.C. Murray and P. Ell, Churchill Livingstone, 1994, pp 877-892.
  209. A Retrospective Analysis of the Cost Effectiveness of Treatment with Metastron in Patients with Prostate Cancer Metastatic to Bone. McEwan AJB, Amyotte GA, McGowan DG, McGillivray JA, Porter AT. In.
  210. Proceedings of the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, Paris, France June 22-24, 1994. Ed: G. Murphy, S. Khoury, C. Chatelain, L. Denis, Scientific Communications International Ltd, 1994, pp 377-385.
  211. A new marker for the detection of adenocarcinomas by radioimmunoscintigraphy. Noujaim AA, Sykes TR, McEwan AJB, MacLean GD, McQuarrie SA, Stanczyk G, Longenecker BM. In: Developments in Nuclear Medicine: Clinical Use of Antibodies, Tumours, infection, infarction, rejection and in the diagnosis of AIDS, ed: R.P. Baum, P.H. Cox, G. Hör and G.L. Buraggi, 1991, pp 151-168.
  212. Biological Considerations in the Evaluation of Tumor-Directed Antibodies for Radioimmunoscintigraphy. Sykes TR, Noujaim AA, McEwan AJB, MacLean GD. In: Proceedings Symposium on Radiopharmacology, ed: D.J. Maddalena, G.M. Snowdon, G.R. Boniface, 1990, pp 164-172.
  213. Radioimmunoscintigraphy with MAb-155 in patients with adenocarcinoma. Sykes TR, McEwan AJB, Woo TK, Borowski AL, MacLean GD, Sykes CJ, Noujaim AA. In: Proceedings Symposium on Radiopharmacology, ed: D.J. Maddalena, G.M. Snowdon, G.R. Boniface, 1990, pp 178-184.
  214. 99mTc hexamethyl propyleneamine oxime (HMPAO) - an animal model of tumour perfusion. McEwan AJB, Ung Y, McQuarrie, SA. In: Proceedings Symposium on Radiopharmacology, ed: D.J. Maddalena, G.M. Snowdon, G.R. Boniface, 1990, pp 96-103.
  215. Immunoradiometric assay for the detection of circulating antibodies to murine monoclonal antibodies in humans (HAMA).Sykes CJ, Sykes TR, McEwan AJ, MacLean GD, Armstrong KJ and Noujaim AA.. In: Proceedings Symposium on Radiopharmacology, ed: D.J. Maddalena, G.M. Snowdon, G.R. Boniface, 1990, pp 204-210.
  216. Positron Emission Tomography and Predicting Tumor Treatment Response. McEwan AJB. In:  Prediction of Tumor Treatment Response, eds: J.D. Chapman, L.J. Peters, H.R. Withers, Pergamon Press 1989, pp277-295.
  217. Tumor-associated Carbohydrate Antigens as Developmentally Regulated and Prognostic Markers: A Novel Integrated Approach using Synthetic Antigens and Corresponding Monoclonal Antibodies. Longenecker BM, MacLean GD, McEwan AJB, Henningsson C, Sykes TR, Selvaraj S, Suresh MR, Noujaim AA. In: Prediction of Tumor Treatment Response, eds: J.D. Chapman, L.J. Peters, H.R. Withers, Pergamon Press 1989, pp39-64.
  218. A Novel Strategy to Derive Monoclonal Antibodies for Successful Imaging of Cancer in Humans. MacLean GD, Noujaim AA, McEwan AJB, Suresh MR, Sykes TR, Marcushamer S, Longenecker BM. In:  The Cellular Basis of Immune Modulation, Alan R. Liss, Inc. New York 1989, pp587-599.
  219. The Potential of Synthetic Tumor-Associated Glycoconjugates (S-TAGs) for Generating Monoclonal Antibodies for Breast Cancer Imaging and for Specific Immunotherapy. MacLean GD, McEwan AJB, Mackie E, Fung P, Henningsson C, Koganty R, Madej M. Sykes T, Noujaim A, Longenecker M. In: Breast Cancer Immunodiagnosis and Immunotherapy, ed: R.L. Cerianai, Plenum Press, 1989.
  220. Synthetic Thomsen Friedenreich Antigens for Production of Anti-Carcinoma Monoclonal Antibodies and Generation of Anti-Carcinoma T Cells. Longenecker BM, MacLean GD, McEwan AJB, Sykes T, Henningsson C, Suresh MR, Noujaim AA. In: Altered Glycosylation in Tumor Cells, Alan R. Liss, Inc., 1988, pp307-320.